ArticlePDF AvailableLiterature Review

Cannabis for Migraine Treatment: The Once and Future Prescription?: An Historical and Scientific Review with Suggestions for Subsequent Studies

  • CReDO Science


Cannabis, or marijuana, has been used for centuries for both symptomatic and prophylactic treatment of migraine. It was highly esteemed as a headache remedy by the most prominent physicians of the age between 1874 and 1942, remaining part of the Western pharmacopoeia for this indication even into the mid-twentieth century. Current ethnobotanical and anecdotal references continue to refer to its efficacy for this malady, while biochemical studies of THC and anandamide have provided a scientific basis for such treatment. The author believes that controlled clinical trials of Cannabis in acute migraine treatment are warranted.
Review Article
Cannabis for migraine treatment: the once and future prescription?
An historical and scientific review
Ethan Russo*
Department of Neurology, Western Montana Clinic, 515 West Front Street, Missoula, MT 58907-7609, USA
Accepted 26 January 1998
Cannabis, or marijuana, has been used for centuries for both symptomatic and prophylactic treatment of migraine. It was highly esteemed
as a headache remedy by the most prominent physicians of the age between 1874 and 1942, remaining part of the Western pharmacopoeia
for this indication even into the mid-twentieth century. Current ethnobotanical and anecdotal references continue to refer to its efficacy for
this malady, while biochemical studies of THC and anandamide have provided a scientific basis for such treatment. The author believes that
controlled clinical trials of Cannabis in acute migraine treatment are warranted. 1998 International Association for the Study of Pain.
Published by Elsevier Science B.V.
Keywords: Migraine; Headache; Cannabis; Marijuana; Dronabinol; Ethnobotany
1. Introduction
One of the basic tenets of medical history is that remedies
fall in and out of favor. Once supplanted, most pharmaceu-
ticals fail to re-attain a position of prominence. Very few are
popular for many decades.
Not many physicians today are aware of the prominence
that Cannabis drugs once held in medical practice. Pro-
blems with quality control and an association with per-
ceived dangerous effects sounded the death knell for
Cannabis as a recognized Western therapy. Other medicines
that are far more potentially damaging than Cannabis
remain in our pharmocopeias because of recognized medi-
cal indications: opiates for pain control, amphetamines for
narcolepsy and attention deficit hyperactivity disorder, etc.
Thalidomide, which was banned due to its role in birth
defects, may be effecting a therapeutic revival. Even the
lowly leech is once again the object of serious medical
This study will examine the history of Cannabis use for
one indication, that of headache treatment, its scientific
rationale, and possible future as an alternative therapeutic
2. Historical and ethnobotanical usage of Cannabis in
migraine treatment
Headaches have likely afflicted man throughout history.
Archeological records substantiate an ancient association
between man and the plant genus Cannabis, plant family,
Cannabaceae. Its botanical origin has been debated to be as
far east as China, but most experts suspect it to be in Central
Asia, possibly in the Pamir Plains (Camp, 1936). Some
botanists have maintained Cannabis as monotypic genus,
while others (Schultes et al., 1974) have provided convin-
cing documentation of three Cannabis species: sativa,
indica, and ruderalis. All contain the psychoactive chemical
delta-9-tetrahydrocannabinol (THC) in varying degree.
Use of Cannabis fibers to make hemp has been documen-
ted as early as 4000 BC by Carbon-14 dating (Li, 1974), and
that use has been maintained continuously up to the present
day. Its seed grain was an ancient human foodstuff, which
may have lead to an early recognition of its medicinal use.
The first records of the latter seem to be in the Pe
Pain 76 (1998) 3–8
0304-3959/98/$19.00 1998 International Association for the Study of Pain. Published by Elsevier Science B.V.
PII S0304-3959(98)00033-5
* Tel.: +1 406 3297238; fax: +1 406 3297453;
Ching, a traditional herbal written down in the first two
centuries AD, but said to be based on the oral traditions
passed down from the Emperor She
ˆn-nung in the third mil-
lenium BC. The text noted that the plant fruits ‘if taken in
excess will produce hallucinations’ (literally ‘seeing dev-
ils’) (Li, 1974).
The Zend-Avesta, the holy book of Zoroastrianism, which
survives only in fragments, dating from around 600 BC in
Persia, alludes to the use of Banga in a medical context, and
it is identified as hemp by the translator (Darmsteter, 1895).
The classical Greek literature also documents knowledge
of the inebriating actions of Cannabis. Herodotus, circa 450
BC, described how the Scythians set up tents, heated stones
and threw Cannabis seeds or flowering tops upon them to
create a vapor, and ‘the Scythians, delighted, shout for joy’.
The Greek physicians Dioscorides and Galen expounded on
medical indications, mainly gastrointestinal (Brunner,
The Atharva Veda of India, dated to between 1400 and
2000 BC referred to a sacred grass, bhang, and medicinal
references to Cannabis were cited by Susrata in the sixth to
seventh centuries AD (Chopra and Chopra, 1957) and
included indication for its use for headache (Dwarakanath,
O’Shaughnessy introduced the medical use of Cannabis
indica, or ‘Indian hemp’, to the West in 1839 (Walton,
1938; Mikuriya, 1973). His treatise on the subject supported
the utility of an extract in patients suffering from rabies,
cholera, tetanus, and infantile convulsions.
Throughout the latter half of the nineteenth century,
many prominent physicians in Europe and North America
advocated the use of extracts of Cannabis indica for the
symptomatic and preventive treatment of headache. Propo-
nents included Weir Mitchell in 1874, E.J. Waring in 1874,
Hobart Hare in 1887, Sir William Gowers in 1888, J.R.
Reynolds in 1890, J.B. Mattison in 1891, and others (Wal-
ton, 1938; Mikuriya, 1973). Cannabis was included in the
mainstream pharmacopeias in Britain and America for this
As late as 1915, Sir William Osler, the acknowledged
father of modern medicine, stated of migraine treatment
(Osler and McCrae, 1915), ‘Cannabis indica is probably
the most satisfactory remedy. Seguin recommends a pro-
longed course’. This statement supports its use for both
acute and prophylactic treatment of migraine.
In 1916, in a quotation attributed to Dr. Dixon, Professor
of Pharmacology, Kings’ College, and the University of
Cambridge (Ratnam, 1916), reference is specifically made
to the therapeutic effects of smoked Cannabis for headache
treatment. He stated, ‘In cases where immediate effect is
desired, the drug should be smoked, the fumes being drawn
through water. In fits of depression, mental fatigue, nervous
headache, feelings of fatigue disappear and the subject is
able to continue his work refreshed and soothed’.
In the years that followed, Cannabis came to be perceived
as a drug of abuse, smoked by certain classes of people as
‘marijuana’ or ‘marihuana’. Nevertheless, it retained adher-
ents for a variety of medical indications, throughout the
early decades of the twentieth century. In 1938 Robert Wal-
ton published a comprehensive review of Cannabis, with
botanical, historical, chemical and political discussions
(Walton, 1938). After discussing the abuse issue, he stated
his belief that the political action that had rendered mari-
juana illegal in the USA in 1937 (and which the American
Medical Association vigorously opposed), should not serve
to prohibit further medical use and scientific investigation of
Cannabis’ possible applications. Walton referred to 12
major authorities on its efficacy for migraine, and only
one detractor.
In 1941, Cannabis preparations were dropped from the
United States Pharmacopeia (U.S.P.), but the following
year, the editor of the Journal of the American Medical
Association still advocated oral preparations of Cannabis
in treatment of menstrual (catamenial) migraine (Fishbein,
1942). This practitioner seemed to prefer Cannabis to ergo-
tamine tartrate, which remains in the migraine armamentar-
ium, some 55 years later.
Thus, Cannabis was touted in eight consecutive decades
in the mainstream Western medical literature as a, or the,
primary treatment for migraine.
As late as 1957, despite governmental controls in that
country, Cannabis drugs retained a role in the indigenous
medicine of India (Chopra and Chopra, 1957), and other
In the 1960s marijuana moved to center stage of Western
consciousness, and attained a degree of notoriety sufficient
to render medical usage inconceivable to most. Medical
research has resumed only recently, spurred on by anecdotal
reports of patients who serendipitously discovered its ben-
efits on their maladies.
3. Modern research developments on Cannabis
In 1974, the first of several studies appeared examining
issues of pain relief with Cannabis (Noyes and Baram,
1974). This article examined five case studies of patients
who volitionally experimented with the substance to treat
painful conditions. Three had chronic headaches, and found
relief by smoking Cannabis that was comparable, or super-
ior to ergotamine tartrate and aspirin.
One subsequent study of Cannabis pertained to pain tol-
erance in an experimental protocol (Milstein et al., 1975). A
statistically significant increase in pain threshold was
observed after smoking Cannabis in both naive (8%
increase) and experienced subjects (16% increase).
Another trial involved oral THC in cancer patients
(Noyes et al., 1975a). They observed a trend toward pain
relief with escalating doses significant to the P,0.001
level. The peak effect occurred at three hours with doses
of 10 and 15 mg, but not until 5 h after ingestion of 20
4E. Russo / Pain 76 (1998) 38
Subsequently, the analgesic effect of THC was compared
to codeine (Noyes et al., 1975b). In essence, 10 mg of oral
THC vs. 60 mg of codeine, and 20 mg of THC vs. 120 mg of
codeine relieved the subjective pain burden of patients by
similar decrements. The effects of 10 mg of THC were well
tolerated, but at 20 mg, sedation and psychic disturbances
bothered many of the elderly Cannabis-naive subjects.
In the 1980s more comprehensive data on pharmacologi-
cal effects of Cannabis and its derivative, THC became
available. In 1983, research with varying potencies of
smoked Cannabis demonstrated some correlation between
serum THC levels and subjective ‘high’ (Chiang and Bar-
nett, 1984). Additionally, experimental subjects were able to
distinguish the potency of the various samples with accu-
In a forensic review (Mason et al., 1985), the issue of
marijuana’s effect on driving was addressed, and it was
indicated that isolated reports of adverse outcomes second-
ary to impairment by Cannabis as a sole inebriant were rare.
The authors concluded that there was no suitable correlation
between plasma or blood levels of THC and the degree of
apparent impairment a human might exhibit.
In 1986 the journal Pharmacological Reviews devoted an
entire issue to Cannabis and cannabinoids. In ‘‘Cellular
Effects of Cannabinoids’’ (Martin, 1986), the author noted
their analgesic properties, but reported that the mode of
action was not blocked by naloxone, and seemed to work
independently of opioid mechanisms.
Another article examined pharmacokinetics (Agurell et
al., 1986). Many facets were presented, including their find-
ings that smoking a standard marijuana cigarette destroyed
30% of available THC.
The final article of the issue was entitled ‘‘Health Aspects
of Cannabis’’ (Hollister, 1986). Pertinent points made
included dose delivery efficiency of THC by inhalation of
10% in marijuana-naive vs. 23% in experience smokers.
Oral bioavailability for THC was only about 6%, and
onset of effects was not seen for 30–120 min.
Smoking of massive Cannabis doses daily for a pro-
longed period produced lower intraocular pressure, serum
testosterone levels, and airway narrowing, but no chromo-
somal aberrations, or impairment of immune responses were
noted (Cohen, 1976).
Other ‘marijuana myths’ were unsupported by careful
review of the literature. While aggravation of pre-existing
psychotic conditions by marijuana use was documented, no
cause and effect relationship was noted. Similarly, chronic
use studies in Jamaica (Comitas, 1976), revealed no deficits
in worker motivation or production. Two studies of brain
computerized tomography (CT scan) refuted prior claims of
heavy use producing cerebral atrophy (Co et al., 1977;
Kuehnle et al., 1977).
With respect to behavior, Hollister refuted the tenet that
depicted Cannabis as a contributor to violent and aggressive
behavior. Concerning addiction, he noted minimal withdra-
wal symptoms of nausea, vomiting, diarrhea, and tremors in
some experimental subjects after very heavy chronic usage.
Such effects were brief and self-limited.
The next year, an article entitled ‘Marijuana and
Migraine’ (El-Mallakh, 1987), presented three cases in
which abrupt cessation of frequent, prolonged, daily mari-
juana smoking were followed by migraine attacks. One
patient noted subsequent remission of headaches with epi-
sodic marijuana use, while conventional drugs successfully
treated the others. The author hypothesized that THC’s per-
ipheral vasoconstrictive actions in rats, or its action to mini-
mize serotonin release from the platelets of human
migraineurs (Volfe et al., 1985), might explain its actions.
In 1988 action was initiated through the DEA to reclas-
sify marijuana to Schedule 2, potentially making it available
for prescription to patients. The DEA administrative law
judge, Francis Young, reviewed a tremendous amount of
testimony from patients, scientists, and politicians in render-
ing his ruling (Young, 1988). Although a medical indication
of marijuana for migraine was not considered, its use was
approved as an anti-emetic, an anti-spasticity drug in multi-
ple sclerosis and paraplegia, while its utilization in glau-
coma was considered reasonable. He stated, ‘By any
measure of rational analysis marijuana can be safely used
within a supervised routine of medical care’.
In 1992, a study examined subjective preferences of
experimental subjects smoking Cannabis, or ingesting oral
THC (Chait and Zacny, 1992). Ten subjects in two trials
preferred smoking active Cannabis over placebo, while 10
of 11 preferred oral THC to placebo. These results call into
serious question the plausibility of true blinding with pla-
cebo preparations in prospective therapeutic drug studies of
marijuana, especially when smoked.
A more profound understanding of Cannabis, THC, and
their actions in the brain has occurred with the discovery of
an endogenous cannabinoid in the human brain, arachido-
nylethanolamide, named anandamide, from the Sanskrit
word ananda, or ‘bliss’ (Devane et al., 1992). This ligand
inhibits cyclic AMP in its target cells, which are widespread
throughout the brain, but demonstrate a predilection for
areas involved with nociception (Herkenham, 1993). The
exact physiological role of anandamide is unclear, but pre-
liminary tests of its behavioral effects reveal actions similar
to those of THC (Fride and Mechoulam, 1993).
Additional research sheds light on possible mechanisms
of therapeutic action of the cannabinoids on migraine. An
inhibitory effect of anandamide and other cannabinoid ago-
nists on rat serotonin type 3 (5-HT
) receptors was demon-
strated (Fan, 1995). This receptor has been implicated as a
mediator of emetic and pain responses. In 1996, a study in
rats demonstrated antinociceptive effects of delta-9-THC
and other cannabinoids in the periaqueductal gray matter
(Lichtman et al., 1996). The PAG has been frequently
cited as a likely anatomic area for migraine generation
(Goadsby and Gundlach, 1991).
The understanding that Cannabis and THC effect their
actions through natural cerebral biochemical processes has
E. Russo / Pain 76 (1998) 38
intensified the public debate on medical benefits of mari-
juana. In 1993, a book entitled Marihuana: The Forbidden
Medicine (Grinspoon and Bakalar, 1993) examined a vari-
ety of claims for ailments treated by marijuana, and includ-
ed an entire section on migraine. One clinical vignette dis-
cussed at length the medical odyssey of a migraineur
through failures with standard pharmaceuticals, and ulti-
mate preference for small doses of smoked marijuana for
symptom control.
The editor of the British Medical Journal (Smith, 1995)
recently wrote an editorial espousing moderation in the drug
war. The Journal of the American Medical Association pub-
lished a supportive commentary in 1995 (Grinspoon and
Bakalar, 1995). The author rated the respiratory risks potent
medical marijuana as low, and pointed out the contradiction
of the Schedule 2 status of synthetic THC, dronabinol, while
its natural source, marijuana remained a Schedule 1 product,
and thus unavailable for legal use to patients who might
prefer its easier dose titration. Grinspoon raised as a theo-
retical possibility the synergistic effects of the whole plant
and its components as compared to pure THC.
The American Journal of Public Health issued its plea
(AJPH, 1996), to allow access to medical marijuana as an
Investigational New Drug (IND).
The Australian government (Hall et al., 1995) recently
compiled a recent exhaustive review of sequelae of Canna-
bis use. In the summary, it states the following acute effects:
Anxiety, dysphoria, panic and paranoia, especially in
naive users;
Cognitive impairment, especially of attention and
memory, for the duration of intoxication;
Psychomotor impairment, and probably an increased
risk of accident if an intoxicated person attempts to
drive a motor vehicle, or operate machinery;
An increased risk of experiencing psychotic symptoms
among those who are vulnerable because of personal
or family history of psychosis;
An increased risk of low birth weight babies if canna-
bis is used during pregnancy.
In a current review of over 65 000 patient records in an
HMO (Sidney et al., 1997), little effect of smoked Cannabis
was seen on morbidity and mortality of non-AIDS patients.
Surely, not all in the medical establishment are convinced
of the relative safety or benefit of Cannabis for medical
usage. In a recent review (Voth and Schwartz, 1997) the
authors concluded, ‘The evidence does not support the
reclassification of crude marijuana as a prescribable medi-
cine’. However, their study was far from comprehensive,
confining itself to the clinical issues of nausea, appetite
stimulation, glaucoma, and spasticity. Methodologically, it
was flawed in that only the medical literature from 1975 to
1996 was screened, an era during which it was quite difficult
to initiate research seeking to support medical indications
for Cannabis. These authors did not examine migraine as an
indication for Cannabis usage, nor did they review the
extensive literature of the past. The debate on the subject
of ‘medical marijuana’ has extended to the World Wide
Web, and includes myriad postings with anecdotal attesta-
tions of efficacy for a variety of indications.
Various investigators have examined the roles of differ-
ent smoke delivery systems (Gieringer, 1996). From these
studies, it is clear that vaporization of marijuana makes it
possible to deliver even high doses of THC to the lungs of a
prospective patient far below the flash point of the Cannabis
leaf, eliminating a fair amount of smoke, containing tar and
other possible carcinogens. However, the marijuana joint
was about as effective as any examined smoking device,
including waterpipes, in providing a favorable ratio of
THC to tar and other by-products of smoking. A standar-
dized smoking procedure for use of Cannabis in medical
research has been developed (Foltin et al., 1988).
Suppository preparations of Cannabis have been used to
advantage in the past, and may be an acceptable form of
administration for the migraineur, although dose titration
would be less available.
4. Discussion
Despite the development of serotonin 1D-agonist medi-
cations, migraine remains a serious public health issue. An
estimated 23 million Americans suffer severe migraine. Of
these, 25% have four or more episodes per month, and 35%
have one to three severe headaches each month (Stewart et
al., 1992). In economic terms, the impact of migraine is
enormous: an estimated 14% of females, and 8% of males
missed a portion of, or an entire day of work or school in one
month (Linet et al., 1989). Migraine has been estimated to
account for an economic impact of US$1.2 to $17.2 billion
annually in the USA in terms of lost productivity (Lipton
and Stewart, 1993).
In 1990 studies were published outlining the biochemical
basis of migraine treatment in serotonin receptor pharma-
cology (Peroutka, 1990). It was this research that led to the
development of the first drugs active on serotonin receptor
subtypes, sumatriptan, and ondansetron.
However, despite the justifiable success of sumatriptan in
treating acute migraine, problems remain. Although rapidly
active subcutaneously, its oral absorption is relatively slow,
and often unreliable in the migraineur. Sumatriptan and its
analogs are ineffective when administered in the ‘aura
phase’ of classic migraine (Ferrari and Saxena, 1995). Addi-
tionally, headache recurrence after ‘triptan’ 5-HT
agents is a not infrequent occurrence. Unfortunately, repe-
titive dosing, and development of agents with longer half-
lives does not seem to avert the issue (Ferrari and Saxena,
Another curiosity in the development of sumatriptan is its
relative inability to pass the blood–brain barrier. Once
more, the development of newer agents with improved cen-
tral nervous system penetration has not necessarily
6E. Russo / Pain 76 (1998) 38
improved efficacy, but does increase the likelihood of side
effects, such as chest and throat tightness, numbness, tin-
gling, anxiety, etc. (Ferrari and Saxena, 1995; Mathew,
1997). Ultimately disappointing, none of the triptan drugs
seems to exert any benefit on the frequency of migraine
incidence, unlike dihydroergotamine, which has degree of
prophylactic benefit.
Thus, it is the author’s contention that this group of
agents, though impressive, may represent somewhat of a
‘therapeutic dead end’. Especially considering the large per-
centages of migraineurs who either fail to respond to the
triptans, or cannot tolerate them, there seems to be definite
need for alternative treatment agents.
The author believes that the issue of medical marijuana,
and its possible role in migraine treatment deserves proper
scientific examination, both biochemically and clinically.
Results of controlled clinical trials may be valuable for
migraineurs and professionals who treat them because there
is a strong need for additional medications that will effec-
tively this condition in its acute state. At this time, the best
available medication, injected sumatriptan (Imitrex) has
been ineffective in up to 30% of patients, or has produced
undesirable side effects for up to 66% when administered
subcutaneously (Mathew, 1997). The available evidence
seems to suggest that smoked Cannabis would be a far
safer alternative than butorphanol nasal spray (Stadol-NS),
which, heretofore, has been an unscheduled drug approved
in the USA for migraine treatment despite its addictive
potential and unfavorable side effect profile (Fisher and
Glass, 1997).
5. Conclusions
1. Cannabis, whether ingested or smoked, has a long his-
tory of reportedly safe and effective use in the treatment
and prophylaxis of migraine.
2. Cannabis has a mild but definite analgesic effect in its
own right.
3. Cannabis seems to affect nociceptive processes in the
brain, and may interact with serotonergic and other path-
ways implicated in migraine.
4. Cannabis is reportedly an effective anti-emetic, a useful
property in migraine treatment.
5. Cannabis, even when abused, has mild addiction poten-
tial, and seems to be safe in moderate doses, particularly
under the supervision of a physician.
6. Cannabis’ primary problem as a medicine lies in its
possible pulmonary effects, which seem to be minimal
in occasional, intermittent use.
7. Cannabis, when inhaled, is rapidly active, obviates the
need for gastrointestinal absorption (impaired markedly
in migraine), and may be titrated to the medical require-
ment of the patient for symptomatic relief.
8. Cannabis delivered by pyrolysis in the form a marijuana
cigarette, or ‘joint’, presents the hypothetical potential
for quick, effective parenteral treatment of acute
In closing, a quotation seems pertinent (Schultes, 1973):
There can be no doubt that a plant that has been in
partnership with man since the beginnings of agricul-
tural efforts, that has served man in so many ways,
and that, under the searchlight of modern chemical
study, has yielded many new and interesting com-
pounds will continue to be a part of man’s economy.
It would be a luxury that we could ill afford if we
allowed prejudices, resulting from the abuse of Can-
nabis, to deter scientists from learning as much as
possible about this ancient and mysterious plant.
The author would like to thank the following individuals:
Rick Doblin and Sylvia Thiessen of the Multidisciplinary
Association for Psychedelic Studies (MAPS), for financial
support, and continued advice and suggestions. Paulette
Cote of Western Montana Clinic Library, and the Inter-
Library Loan Department at the Mansfield Library of the
University of Montana for wonderful service in locating
obscure references. Drs. Tod Mikuriya and Lester Grin-
spoon for provision of books, suggestions and encourage-
ment. Drs. Keith Parker and Vernon Grund of the Depart-
ment of Pharmacy, University of Montana for their gui-
dance and good sense. Drs. Varro Tyler and Dennis
McKenna for their inspiration and the confidence they
engendered. Dr. Donald Abrams for his continuing efforts
in pursuit of medical indications for Cannabis. The Herbal
Research Foundation and NAPRALERT for assistance on
ethnobotanical information. Dr. Samir Ross for his initial
guidance on my inquiries about experimental research on
Cannabis. Marie-Jose´e Thibault, Deborah Somerville, and
Penny King for their faithfulness and ‘moral support’. Ulti-
mately, to Dr. Mark Russo, for reasons he alone will under-
Agurell, S., Halldin, M., Lindgren, J.-E., Ohlsson, A., Widman, M.,
Gillespie, H. and Hollister, L., Pharmacokinetics and metabolism of
delta-1-tetrahydrocannabinol and other cannabinoids with emphasis on
man, Pharmacol. Rev., 38 (1986) 21–43.
AJPH, Access to therapeutic marijuana/cannabis, Am. J. Public Health, 86
(1996) 441–442.
Brunner, T.F., Marijuana in ancient Greece and Rome? The literary
evidence, J. Psychedel. Drugs, 9 (1977) 221–225.
Camp, W.H., The antiquity of hemp as an economic plant, J. N. Y. Bot.
Gard., 37 (1936) 110–114.
Chait, L.D. and Zacny, J.P., Reinforcing and subjective effects of oral
delta-9-THC and smoked marijuana in humans, Psychopharmacology,
107 (1992) 255–262.
E. Russo / Pain 76 (1998) 38
Chiang, C.N. and Barnett, G., Marijuana effect and delta-9-tetrahydrocan-
nabinol plasma level, Clin. Pharm. Ther., 36 (1984) 234–238.
Chopra, I.C. and Chopra, R.W., The use of cannabis drugs in India, Bull.
Narcotics, 9 (1957) 4–29.
Co, B.T., Goodwin, D.W., Gado, M., Mikhael, M. and Hill, S.Y., Absence
of cerebral atrophy in chronic cannabis users by computerized transaxial
tomography, J. Am. Med. Assoc., 237 (1977) 1229–1230.
Cohen, S., The 94-day cannabis study, Ann. N. Y. Acad. Sci., 282 (1976)
Comitas, L., Cannabis and work in Jamaica: a refutation of the amotiva-
tional syndrome, Ann. N. Y. Acad. Sci., 282 (1976) 211–220.
Darmsteter, J. (trans.), The Zend-Avesta, Part I, The Vendı
ˆd, Oxford,
London, 1895, 389 pp.
Devane, W.A., Hanus, L., Breuer, A., Pertwee, R.G., Stevenson, L.A.,
Griffin, G., Gibson, D., Mandelbaum, A., Etinger, A. and Mechoulam,
R., Isolation and structure of a brain constituent that binds to the can-
nabinoid receptor, Science, 258 (1992) 1946–1949.
Dwarakanath, C., Use of opium and cannabis in the traditional systems of
medicine in India, Bull. Narcotics, 17 (1965) 15–19.
El-Mallakh, R.F., Marijuana and migraine, Headache, 27 (1987) 442
Fan, P., Cannabinoid agonists inhibit the activation of 5-HT3 receptors in
rat nodose ganglion neurons, J. Neurophysiol., 73 (1995) 907–910.
Ferrari, M.D. and Saxena, P.R., 5-HT1 receptors in migraine pathophy-
siology and treatment, Eur. J. Neurol., 2 (1995) 5–21.
Fishbein, M., Migraine associated with menstruation, J. Am. Med. Assoc.,
237 (1942) 326.
Fisher, M.A. and Glass, S., Butorphanol (Stadol): a study in problems of
current drug information and control, Neurology, 48 (1997) 1156–1160.
Foltin, R.W., Fischman, M.W. and Byrne, M.F., Effects of smoked mar-
ijuana on food intake and body weight of humans living in a residential
laboratory, Appetite, 11 (1988) 1–14.
Fride, E. and Mechoulam, R., Pharmacological activity of the cannabinoid
receptor agonist, anandamide, a brain constituent, Eur. J. Pharmacol.,
231 (1993) 313–314.
Gieringer, D., Waterpipe study, Bull. Multidisc. Assoc. Psychedel. Stud., 6
(1996) 59–63.
Goadsby, P.J. and Gundlach, A.L., Localization of [
mine binding sites in the cat central nervous system: relevance to
migraine, Ann. Neurol., 29 (1991) 91–94.
Grinspoon, L. and Bakalar, J.B., Marihuana: The Forbidden Medicine,
Yale University, New Haven, CT, 1993, 184 pp.
Grinspoon, L. and Bakalar, J.B., Marihuana as medicine: a plea for
reconsideration, J. Am. Med. Assoc., 273 (1995) 1875.
Hall, W., Solowij, N. and Lemon, J., The Health and Psychological Con-
sequences of Cannabis Use, National Drug Strategy Monograph Series
No. 25, National Drug and Alcohol Research Centre, Australia, 1995.
Herkenham, M.A., Localization of cannabinoid receptors in brain: rela-
tionship to motor and reward systems. In: S.G. Koreman and J.D.
Barchas (eds.), Biological Basis of Substance Abuse, Oxford University
Press, London, 1993, pp. 187–200.
Hollister, L.E., Health aspects of cannabis, Pharmacol. Rev., 38 (1986) 1–
Kuehnle, J., Mendelson, J.H., Davis, K.R. and New, P.F.J., Computed
tomographic examination of heavy marihuana smokers, J. Am. Med.
Assoc., 237 (1977) 1231–1232.
Li, H.-L., An archaeological and historical account of cannabis in China,
Econ. Bot., 28 (1974) 437–448.
Lichtman, A.H., Cook, S.A. and Martin, B.R., Investigation of brain sites
mediating cannabinoid-induced antinociception in rats: evidence sup-
porting periaqueductal gray involvement, J. Pharmacol. Exp. Ther.,
276 (1996) 585–593.
Linet, M.S., Stewart, W.F. and Celentano, D.D., An epidemiological study
of headache among adolescents and young adults, J. Am. Med. Assoc.,
261 (1989) 2211–2216.
Lipton, R.B. and Stewart, W.F., Migraine in the United States: epidemiol-
ogy and health care use, Neurology, 43 (suppl. )(1993) 610.
Martin, B.R., Cellular effects of cannabinoids, Pharmacol. Rev., 38 (1986)
Mason, A.P. and McBay, A.J., Cannabis: pharmacology and interpretation
of effects, J. Forens. Sci., 30 (1985) 615–631.
Mathew, N.T., Serotonin 1D (5-HT 1D) agonists and other agents in acute
migraine, Neurol. Clinics, 15 (1997) 61–83.
Mikuriya, T.H. (Ed.), Marijuana: Medical Papers 1839–1972, Medi-Comp
Press, Oakland, CA, 1973, 465 pp.
Milstein, S.L., MacCannell, K., Karr, G. and Clark, S., Marijuana-pro-
duced changes in pain tolerance: experienced and non-experienced
subjects, Int. Neuropsychiatr., 10 (1975) 177–182.
Noyes, R. and Baram, D.A., Cannabis analgesia, Comp. Psychiatr., 15
(1974) 531–535.
Noyes, R., Brunk, F., Baram, D.A. and Canter, A., Analgesic effect of
delta-9-tetrahydrocannabinol, J. Clin. Pharmacol., 15 (1975a) 134–143.
Noyes, R., Brunk, F., Avery, D.H. and Canter, A., The analgesic properties
of delta-9-tetrahydrocannabinol and codeine, Clin. Pharmacol. Ther., 18
(1975b) 84–89.
Osler, W. and McCrae, T., The Principles and Practice of Medicine,
Appleton, New York, 1915, 1225 pp.
Peroutka, S.J., Developments in 5-hydroxytryptamine receptor pharmacol-
ogy in migraine, Neurol. Clinics, 8 (1990) 829–839.
Ratnam, E.V., Cannabis indica, J. Brit. Med Assoc., Ceylon Branch, 13
(1916) 30–34.
Schultes, R.E., Man and marijuana, Nat. Hist., 82 (1973) 59–63, 80, 82.
Schultes, R.E., Klein, W.M., Plowman, T. and Lockwood, T.E., Cannabis:
an example of taxonomic neglect, Bot. Mus. Leafl. Harvard Univ., 23
(1974) 337–367.
Sidney, S., Beck, J.E., Tekawa, I.S., Quesenberry, C.P. and Friedman,
G.D., Marijuana use and mortalilty, Am. J. Public Health, 87 (1997)
Smith, R., Editorial: the war on drugs, Br. Med. J., 311 (1995) 23–30.
Stewart, W.F., Lipton, R.B. and Celantano, D.D., Prevalence of migraine
headache in the United States, J. Am. Med. Assoc., 267 (1992) 64–69.
Volfe, Z., Dvilansky, A. and Nathan, I., Cannabinoids block release of
serotonin from platelets by plasma from migraine patients, Int. J. Clin.
Pharm. Res., 4 (1985) 243–246.
Voth, E.A. and Schwartz, R.H., Medical applications of delta-9-tetrahy-
drocannabinol and marijuana, Ann. Intern. Med., 126 (1997) 791–798.
Walton, R.P., Marihuana: America’s New Drug Problem: A Sociologic
Question with its Basic Explanation Dependent on Biologic and Med-
ical Principles, Lippincott, Philadelphia, PA, 1938, 223 pp.
Young, F.L., In the Matter of Marijuana Rescheduling Petition, Depart-
ment of Justice, Drug Enforcement Administration. Docket 86-22, Drug
Enforcement Administration, Washington, DC, September 6, 1988.
8E. Russo / Pain 76 (1998) 38
... There is medical evidence showing that CBD may be effective in treatment of a wide range of disorders including epilepsy, Alzheimer's disease, Parkinson's disease, Huntington's disease, anxiety disorders including PTSD, depression, dystonia, Meige's syndrome, schizophrenia and psychosis,stroke and hypoxic-ischemic injury, spinal cord injury, inflammatory disorders, psoriasis, rheumatoid arthritis,a wide range of cancers across multiple organ system, inflammatory bowel diseases, nausea, appetite suppressant and weight loss, bone formation, osteoporosis and fracture healing, hepatic encephalopathy and cirrhosis, cardiovascular diseases including hypertension, cardiomyopathy and myocardial ischemia, and diabetic complications. 8,9,10,11 Unlike THC, CBD does not have any psychoactive effect, scientists even confirmed its antipsychotic and anxiolytic effect and the reduction of some side effects of THC. 12 Many researchers prooved, that CBD possesses anti-inflammatory, anti-nociceptive and muscle relaxing properties. 13 This is the reason why researchers are increasingly trying to find the way of using CBD in patients suffering from TMD and orofacial pain. ...
Full-text available
Introduction: Temporomandibular disorders (TMD) and orofacial pain present therapeutic challenges. Interest in the use of CBD-based medications has outpaced the knowledge of its efficacy and safety in treating TMD. The objective of this review was to evaluate the effectiveness of CBD-based medications in individuals with TMD. Materials and Methods: The PubMed, Embase, Scopus databases were examined. The search was filtered to include only papers published from 2007 to 2022. The main question was asked: Can CBD/Cannabis play an important role in the therapy of orofacial pain and TMD? Results: After applying the inclusion and exclusion criteria and analyzing the abstracts, 31 articles were finally selected. Conclusions: CBD should be taken into consideration in the therapy of masticatory muscles in patients with TMD and orofacial pain. Further research is needed for CBD administration.
... On the other hand, plant species can influence the quantity and quality of essential oils extracted. (Russo et al., 1998). Activity Scavenging of the ABTS ・ + radical: ...
... Cannabis was mentioned in early British and American pharmacopeias for the treatment of headache and pain [14]. Brown-Sequard developed multiple combination tinctures of cannabis for many chronic pain conditions. ...
Full-text available
Purpose of Review Public acceptance of Cannabis sativa L. (cannabis) as a therapeutic option grows despite lags in both research and clinician familiarity. Cannabis—whether as a medical, recreational, or illicit substance—is and has been commonly used by patients. With ongoing decriminalization efforts, decreased perception of harms, and increased use of cannabis in the treatment of symptoms and disease, it is critical for clinicians to understand the rationale for specific therapies and their medical and practical implications for patients. In view of the opioid crisis, overall patient dissatisfaction, and lack of adherence to current chronic pain and headache therapies, this review provides up-to-date knowledge on cannabis as a potential treatment option for headache pain. Recent Findings Research into the use of cannabinoids for disease treatment have led to FDA-approved drugs for seizures, nausea, and vomiting caused by cancer chemotherapy; and for decreased appetite and weight loss in people with HIV/AIDS. For a wide variety of conditions and symptoms (including chronic pain), cannabis has gained increasing acceptance in society. The effects of cannabidiol (CBD) and tetrahydrocannabinol (THC) in pain pathways have been significantly elucidated. An increasing number of retrospective studies have shown a decrease in pain scores after administration of cannabinoids, as well as long-term benefits such as reduced opiate use. Yet, there is no FDA-approved cannabis product for headache or other chronic pain disorders. More is being done to determine who is likely to benefit from cannabis as well as to understand the long-term effects and limitations of the treatment. Summary Cannabis can refer to a number of products derived from the plant Cannabis sativa L. Relatively well-tolerated, these products come in different configurations, types, and delivery forms. Specific formulations of the plant have been shown to be an effective treatment modality for chronic pain, including headache. It is important for clinicians to know which product is being discussed as well as the harms, benefits, contraindications, interactions, and unknowns in order to provide the best counsel for patients.
... Current ethnobotanical and anecdotal references mention efficacy. Biochemical studies of THC and anandamide have provided a scientific basis for both symptomatic and prophylactic treatment of migraine [25]. Dronabinol and nabilone, synthetic cannabinoids, have been shown to act in place of first-line therapy for cluster headaches (triptans, verapamil) and can effectively control pain [16,26]. ...
Full-text available
Cannabis has been long used since ancient times for both medical and recreational use. Past research has shown that cannabis can be indicated for symptom management disorders, including cancer, chronic pain, headaches, migraines, and psychological disorders (anxiety, depression, and post-traumatic stress disorder). Active ingredients in cannabis that modulate patients' perceptions of their conditions include Δ9-tetrahydrocannabinol (THC), cannabidiol (CBD), flavonoids, and terpenes. These compounds work to produce effects within the endocannabinoid system to decrease nociception and decrease symptom frequency. Research within the United States of America is limited to date due to cannabis being classified as a schedule one drug per the Drug Enforcement Agency. Few anecdotal studies have found a limited relationship between cannabis use and migraine frequency. The purpose of the review article is to document the validity of how medical cannabis can be utilized as an alternative therapy for migraine management. Thirty-four relevant articles were selected after a thorough screening process using PubMed and Google Scholar databases. The following keywords were used: "Cannabis," "Medical Marijuana," "Headache," "Cannabis and Migraine," "Cannabis and Headache." This literature study demonstrates that medical cannabis use decreases migraine duration and frequency and headaches of unknown origin. Patients suffering from migraines and related conditions may benefit from medical cannabis therapy due to its convenience and efficacy.
... yüzyılın başlarında birçok önde gelen doktor tarafından desteklenmiştir. Esrar, bu erken yıllarda baş ağrısı tedavisi için İngiliz ve Amerikan farmakopelerine dahil edilmiştir (Russo, 1998). ...
Full-text available
Geçmişte pek çok bitki, bitki parçası, meyvesi, tohumu ve bunlardan hazırlanan ürünler (iksirler ve karışımlar) tedavi amaçlı olarak kullanılmıştır. Bugün farmasötik sanayide gelinen aşamadan dolayı geçmişe bakıldığında, kullanılan birçok iksirlerin ve karışımların işe yaramadığı, hatta bazılarının zararlı bile olduğu bilinmektedir. Bununla birlikte, bazı bitkilerin bazı hastalıklara farklı mekanizmalarla olumlu etkileri olabildiği bilimsel olarak kanıtlanırken aynı zamanda bir kısmı ilaç etken maddesi olarak eczanelerde de yer alabilmektedir. Bu bitkilerden biri olan kenevir, insanlar tarafından yüzyıllar boyunca tekstil lifi, ilaç, keyif verici madde, tıbbı tedavi amaçlı olarak ve dini ritüellerde günlük adanma işlemleri sırasında kullanılmıştır.
Full-text available
Kenevir ve endüstri
Full-text available
Kenevirin tıpta yeri
Background The cultivation and use of cannabis is historically rooted in the Indian subcontinent and this rich heritage of cannabis use dates back to at least two thousand years. Cannabis remains an illicit substance in India despite its changing status globally with many countries legalizing cannabis use in recent years. Scientific research on cannabis use in India has also been sparse. Method Extensive search of online databases resulted in the identification of 29 original research studies pertaining to one of three areas of cannabis research; a) prevalence of cannabis use b) psychological correlates of cannabis use, c) cannabis use in substance use treatment settings. Findings We found that most Indian studies used very basic quantitative research designs and had poor scientific rigor. Samples were small, region specific and included only males. Data analyses were limited to descriptive methods. The criteria for cannabis use in most of the reviewed studies were not rigorous and prone to biases. Conclusion & Implications With changing attitudes and loosening of restrictions on cannabis use, the prevalence of new users is rising dramatically particularly in the college going population. This presents a strong need for research on motivations and attitudes to cannabis use and how those can influence patterns of use, and also the short- and long-term effects of use. More studies with stronger research designs (both cross sectional and longitudinal) are required for the study of cannabis use and this knowledge will be critical for managing the growing substance epidemic, generating public health solutions as well as formulating effective policy frameworks.
The worldwide interest and push for the legalization of cannabis/marijuana, especially in the United States, are increasing with each passing day. The present article deals with the concise yet broad review of chemical, medicinal (neuroprotection), and adverse psychotic aspects of cannabis (marijuana or marihuana). The emphasis is made to understand the influence of tetrahydrocannabinol (THC) on a broad spectrum of properties ranging from psychosis, neuroprotection, neurotoxicity to medicinal. The reason why THC shows psychoactivity, but cannabidiol (CBD) does not, has been elucidated based on the minor difference in their chemical structures inhibiting CBD to bind with cannabinoid receptors due to steric hindrance. The distribution of cannabinoid receptors (namely, CB1 and CB2) in the human body and the role of endocannabinoids (namely, anandamide and 2-arachidonoyl glycerol) throughout the human system are described. The effect of the method of consumption (inhalation vs. ingestion) on the psychotropicity of cannabis/THC has also been discussed. Additionally, the effect of the use of synthetic endocannabinoid receptor blocker (antagonist) as a drug molecule for a specific purpose, such as for reducing the appetite, to treat obesity, or for the treatment of tobacco, alcohol, and other hard drugs induced addiction, and their potential adverse effects are also the focus of the article. Both the benefits and the risks of consuming cannabinoids are mainly dose-dependent, just like any other legal or prescription pharma products or regulated/unregulated psychotropic substances. Moderation is the right old prescription for a healthy and long productive life, and it applies to the use of medicinal, cultural, and/or recreational products like cannabis/cannabinoids. The traditional use of cannabis leaves (bhang) in India for medical as well as cultural purposes has been discussed from the modern scientific perspective. Lastly, the rapidly growing trend of the number of the publication of both the scientific research papers and the patent applications on cannabis, along with the market trend of cannabis-derived products, has been provided, showing quite high and promising growth.
PURPOSE Late abnormalities of left ventricular (LV) performance occur in most survivors of childhood acute lymphoblastic leukemia (ALL) treated with moderate anthracycline doses. We studied the prevalence of late cardiotoxicity in patients treated with lower anthracycline doses and related this to survival. PATIENTS AND METHODS Echocardiograms were performed in 50 normal children and 120 relapse-free ALL survivors 6.2 +/- 2.0 years after the end of cumulative daunorubicin doses of 90 mg/m2 (n = 40), 180 mg/m2 (n = 40), or 270 mg/m2 (n = 40) on UKALL X pilot (1982 to 1984) or UKALL X (1985 to 1989) protocols. Age at treatment onset was 4.7 +/- 2.8 years. Cardiac abnormalities were reviewed in light of the UKALL X 5-year disease-free survival rates of 57% (95% confidence interval [CI], 51% to 63%), 61% to 62% (95% CI, 56% to 68%), and 71% (95% CI, 66% to 76%) for the groups that received 90, 180, and 270 mg/m2 of daunorubicin, respectively. RESULTS ALL survivors had reduced LV fractional shortening (FS) compared with normal (32.3% +/- 4.4% v 35.9% +/- 4.2%, P < .005), which was accounted for by increased LV end-systolic stress (49.4 +/- 13.5 v 42.2 +/- 9.1 g/cm2, P < .001), whereas LV contractility independent of loading conditions was normal for the group as a whole. Of 27 patients (23%) with cardiac abnormalities, 25 (21%) had increased end-systolic stress, whereas only two (2%) had reduced contractility. The proportion with cardiac abnormality was similar in the three dose groups. Anthracycline dose, age at treatment, sex, follow-up duration, growth hormone, pubertal status, hemoglobin level, and total WBC count at presentation were not predictive of increased LV end-systolic stress. CONCLUSION There was a reduced incidence and severity of cardiac abnormalities with the lower anthracycline dose protocols (90 to 270 mg/m2) studied compared with previous reports in which subjects had received moderate anthracycline doses (approximately 300 to 550 mg/m2). Cumulative anthracycline dose within the range 90 to 270 mg/m2 did not relate to cardiac abnormalities. This suggests that there may be no safe anthracycline dose to avoid late cardiotoxicity, but reinforces the use of the protocol that affords best survival within the dose range studied.
In 1971, Campbell et al. reported pneumoencephalographic evidence of cerebral atrophy in ten young men with histories of heavy cannabis use. Four had neurological symptoms, and five had some degree of intellectual impairment. Computerized transaxial tomography (CTT) studies of 12 young men having histories of heavy cannabis smoking revealed no evidence of cerebral atrophy.
Despite extensive description of headache among patients in specialty clinics and general practices in the United States, there have been few community-wide investigations. In a population-based telephone interview study of 10 169 Washington County, Maryland, residents who were 12 through 29 years old, 57.1% of males and 76.5% of females reported that their most recent headache occurred within the previous 4 weeks. Four or more headaches in the preceding month were reported by 6.1% of males and 14.0% of females. The average duration of the subjects' most recent headache was 5.9 hours for males and 8.2 hours for females; 7.9% and 13.9%, respectively, missed part of a day or more of school or work because of that headache. Within the month before interview, 3.0% of males and 7.4% of females had suffered from a migraine headache. Consultations with a physician, by specialty, for headache-related problems are described by sex and age of subjects, as is the use of specific prescription and nonprescription medications. (JAMA. 1989;261:2211-2216)
Computed tomographic scans were obtained from 19 men with long histories of heavy marijuana smoking and who were also observed to smoke large amounts of marijuana under research ward conditions. The ventricular system and subarachnoid spaces were normal in size and showed no indication of atrophic change. (JAMA 237:1231-1232, 1977)